CTLA4 and prostate cancer: In support of this hypothesis, a recent report described the use of TH-302 in prostate cancer models and showed that, by using the HAP to target hypoxia, T cell infiltration was increased and sensitivity to CTLA-4 and PD-1 blockade was restored (Jayaprakash et al., 2018).